Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 7/20 | 0.52 |
| ▸ | RAF1 | P04049 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764085 | 0.80 | MAPK14 (0.69) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL1271530 | 0.80 | NPC1 (0.52) | PIK3CABRAFRAF1NPC1RAB9A | |
| SCHEMBL5896834 | 0.78 | MAPK14 (0.66) | MAPK13MAPK14PIK3CABRAFRAF1 | |
| SCHEMBL12764177 | 0.78 | MAPK14 (0.65) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL6166915 | 0.78 | NPC1 (0.58) | MAPK13MAPK14BRAFRAF1NPC1 | |
| SCHEMBL1663772 | 0.77 | HDAC8 (0.59) | NPC1RAB9AMAPT | |
| SCHEMBL31524076 | 0.77 | MAPK14 (0.66) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL4827539 | 0.77 | MAPK14 (0.66) | MAPK13MAPK14BRAFRAF1HSPB1 | |
| SCHEMBL5897176 | 0.77 | MAPK13 (0.62) | MAPK13MAPK14PIK3CABRAFRAF1 | |
| SCHEMBL4833700 | 0.77 | MAPK13 (0.61) | MAPK13MAPK14PIK3CABRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | FREDERICKSON MARTYN (GB) | 2005-06-09 | — | — | US | disclosed |
| EP-1495016-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | Astex Technology Limited (GB) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003087087-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE | ASTEX TECHNOLOGY LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124620-A1 | Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's | MAPK1, IDO1, INMT | MAPK13 36/4885MAPK14 17/4885PIK3CA 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.